newsRoche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancerRoche announced topline results of its first randomized trial of…7 April 2011 | By RocheRoche announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer...
newsRoche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinomaRoche today announced that a pivotal Phase II clinical study…21 March 2011 | By RocheRoche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results...
newsEuropean Commission continues to support AvastinAvastin in combination with paclitaxel will remain a treatment option…2 March 2011 | By RocheAvastin in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe...
newsFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphomaRoche announced that the U.S. FDA approved Rituxan/MabThera as a…31 January 2011 | By RocheRoche announced that the U.S. FDA approved Rituxan/MabThera as a maintenance treatment for patients with advanced follicular lymphoma...
newsPhase II study with first-in-class investigational drug demonstrates improvement in negative symptoms in patients with schizophreniaRoche today presented eight-week results from a phase II study…6 December 2010 | By F. Hoffmann-La Roche LtdRoche today presented eight-week results from a phase II study of RG16781...
